Wealth Enhancement Advisory Services’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$669K	Buy	6,661 +415	+7%	+$37.4K	﹤0.01%	2420
2026 Q1	$544K	Buy	6,246 +1,550	+33%	+$136K	﹤0.01%	2253
2025 Q4	$397K	Buy	4,696 +489	+12%	+$39K	﹤0.01%	2663
2025 Q3	$316K	Buy	4,207 +240	+6%	+$16.6K	﹤0.01%	2745
2025 Q2	$264K	Buy	+3,967	New	+$258K	﹤0.01%	2743
2025 Q1	–	Sell	-4,298	Closed	-$282K	–	3053
2024 Q4	$282K	Buy	4,298 +1,065	+33%	+$73.3K	﹤0.01%	2427
2024 Q3	$228K	Sell	3,233 -12	-0.4%	-$836	﹤0.01%	2366
2024 Q2	$215K	Buy	+3,245	New	+$213K	﹤0.01%	2239

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Wealth Enhancement Advisory Services's IHE Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its iShares US Pharmaceuticals ETF (IHE) stake by 6.6% in Q2 2026, buying an estimated $37.4K and bringing the position to 6,661 shares worth $669K. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

Wealth Enhancement Advisory Services first reported a position in IHE in Q2 2024 and has held it in 8 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Wealth Enhancement Advisory Services held 6,661 shares of iShares US Pharmaceuticals ETF worth $669K as of Q2 2026.
Wealth Enhancement Advisory Services bought 415 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $37.4K.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2420 holding.
Wealth Enhancement Advisory Services first reported a position in iShares US Pharmaceuticals ETF in Q2 2024 and has held it in 8 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.